GALENIKA ANNOUNCES DISTRIBUTION OF PRODUCTS FROM THE AESTHETIC MEDICINE SEGMENT
With a new global partner, Galenika continues to expand its derma portfolio
Belgrade, Decembar 4, 2024 – Pharmaceutical company Galenika continues to strategically expand its portfolio, this time through a partnership with the Austrian company Croma-Pharma, which is present in markets globally and is one of the leading European manufacturer of premium products based on hyaluronic acid, an important ingredient for skin care.
Galenika hereby launches the distribution of seven new products from the segment of aesthetic medicine, for the markets of Serbia and Bosnia and Herzegovina. Croma-Pharma operates in 80 markets around the world, and has the highest quality standards, which is the main prerequisite for this partnership.
The new five-year cooperation agreement with Croma-Pharma additionally strengthens Galenika’s market position and enables further expansion of the portfolio of modern and effective pharmaceutical products of the highest quality.
“With this partnership, Galenika consistently continues to expand its product portfolio in a segment that is increasingly important today. Entering the field of aesthetic medicine is a significant step for the company, and at the same time we are continuing to expand the derma-portfolio of our products that are already present on the market. We are glad to have found a global partner who, such as Galenika, is committed to health and the highest quality of products,” said Ricardo Vian Marques, General Manager of Galenika.
Croma-Pharma is a leader in the product segment for minimally invasive aesthetic procedures and is present with its products in as many as 80 markets worldwide, including Europe, USA, Canada, China and Australia and New Zealand. The company offers a comprehensive and innovative portfolio in the segment of aesthetic medicine. In addition to aesthetic medicine, Croma-Pharma also produces medicinal products based on hyaluronic acid for use in orthopedics and ophthalmology, which are of increasing importance in medicine. In addition, the company invests significantly in research and development of new products. By applying its own innovative crosslinking technology (MACRO Core Technology), it ensures production with predefined high-quality characteristics.
Leave a reply“Aesthetic medicine has become much more than what it used to be.” At Croma-Pharma, we are driven by the ambition to constantly find value for our partners. Quality, reliability and a scientific approach have led us to position ourselves both on the domestic and global markets. We recognized that Galenika shares our values and therefore we believe that it is the right partner and will be a long-term supporter of cooperation in achieving common global goals,” said Andreas Prinz, CEO of Croma-Pharma.